Clinical Research Directory

Inclusion Criteria: 1. Adult women and men (≥ 18 years of age) with proven initial diagnosis of HCC with evidence of loco-regional recurrent or advanced disease not amenable to resection. 2. At least one cycle of therapy with ATZ plus BEV. 3. Eligible individuals will be required to have Baseline (pre-index) EGD available 4. No prior systemic therapy for HCC. 5. Evaluable disease as defined per modified Response Evaluation Criteria in Solid Tumours (mRECIST) V1.1 criterion (At least 1 evaluable CT result over the entire available index and post-index period, excluding the baseline). 6. Patients identified from the patient registry in the hospital with treatment charts between April 1, 2022- December 31, 2024 (index date). 7. Eligible individuals will be required to have data available prior to the index date (pre-index period; baseline characteristics). Exclusion Criteria: 1. A diagnosis of any other primary cancer prior to the index date 2. ATZ plus BEV treatment as part of a clinical trial 3. ATZ or BEV given off-label 4. Patients with incomplete medical records 5. Patients receiving other investigational drugs 6. History of hepatic encephalopathy 7. Patients with brain metastasis 8. HBV and HBC co-infection